Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Medarex raises $12.9M in IPO for R&D of Biospecific

Executive Summary

Medarex (develops pharmaceuticals for the treatment of AIDS, infectious disease, cancer and autoimmune disease) completed its IPO of 2,300,000 shares of common stock at $6.10 per share and 2,250,000 Redeemable Warrants.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies